Belite Bio (BLTE) Reiterated at Buy by Benchmark on Tinlarebant NDA Acceptance by FDA
Tweet Send to a Friend
Benchmark analyst Bruce D. Jackson reiterated a Buy rating and $217.00 price target on Belite Bio, Inc, ADR (NASDAQ: BLTE) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
